报价延迟最少15分钟:2026/08/29 22:32 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.51 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-6.65/--
|
|
企业价值
11.59M
|
| 资产负债 |
|
每股账面净值
8.38
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
6.20K
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Aspire Biopharma Holdings Inc is an early-stage biopharmaceutical company focused on developing and commercializing novel sublingual drug delivery technologies. The company is mainly engaged in advancing patent-pending formulations designed to enable rapid absorption of drugs, initially targeting high-dose aspirin products for cardiovascular and pain management applications. Its technology aims to improve efficacy and response time by bypassing the gastrointestinal tract through sublingual delivery. |
